Diabetes and metabolic syndrome (MS)

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Disorders

Background:

• Metabolic syndrome (MS) is strongly linked to increased cardiovascular disease (CVD) morbidity and mortality.
• MS is characterized by metabolic alterations (hyperglycemia, hyperlipemia), chronic inflammation, and endothelial dysfunction, all stemming from insulin resistance.
• Cluster analysis identifies four key MS factors: metabolic, pressure, lipid, and obesity, underscoring its complex nature and substantial CVD risk contribution.

Purpose of the Study:

• To highlight the significant cardiovascular risk associated with metabolic syndrome.
• To discuss the role of insulin resistance as the common denominator in MS.
• To evaluate the mandatory use of statins in managing CVD risk in MS patients.

Main Methods:

• Literature review of studies on metabolic syndrome and cardiovascular disease.
• Analysis of cluster analysis findings defining MS factors.
• Examination of the efficacy of statin therapy in MS patients with specific lipid profiles.

Main Results:

• Metabolic syndrome confers substantial additional cardiovascular risk beyond individual risk factors.
• Statin therapy demonstrates beneficial effects on cardiovascular mortality in MS patients.
• The benefits of statins are observed even when low-density lipoprotein (LDL)-cholesterol levels are normal, and despite typical MS dyslipidemia (high triglycerides, low HDL-cholesterol).

Conclusions:

• Insulin resistance is the central mechanism linking metabolic alterations and endothelial dysfunction in MS.
• Patients with MS face a high risk of future CVD, necessitating statin treatment.
• Statin therapy is mandatory for patients with MS to mitigate cardiovascular risk, irrespective of LDL cholesterol levels.